Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 14/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16420518 | 0.90 | ATR (0.67) | ATRNOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16420534 | 0.87 | ATR (0.65) | ATRNPC1RAB9ASMN1; SMN2ATAD2 | |
| SCHEMBL16420584 | 0.86 | ATR (0.60) | ATRNPC1RAB9ASMN1; SMN2ATAD2 | |
| SCHEMBL16420607 | 0.86 | ATR (0.66) | ATRNOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17826148 | 0.85 | ATR (0.54) | ATRNPC1RAB9ASMN1; SMN2ATAD2 | |
| SCHEMBL16420700 | 0.84 | ATR (0.70) | ATRNPC1RAB9A | |
| SCHEMBL17826199 | 0.84 | ATR (0.55) | ATRNPC1RAB9ASMN1; SMN2PIM1 | |
| SCHEMBL17826184 | 0.84 | ATR (0.55) | ATRNPC1RAB9ASMN1; SMN2ATAD2 | |
| SCHEMBL16420535 | 0.84 | ATR (0.67) | ATRNPC1RAB9ASMN1; SMN2ATAD2 | |
| SCHEMBL16420582 | 0.84 | ATR (0.67) | ATRNPC1RAB9ASMN1; SMN2ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885NOTUM 4460/4885NPC1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.